Hepato-splenic T-cell Lymphoma
1 clinical trials · Condition
◉ Watch Hepato-splenic T-cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) (NCT02588651) | Deepa Jagadeesh | 2016-06-17 |
Track Hepato-splenic T-cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.